An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Phase 1/2 Active not recruiting 23 enrolled Rakuten Medical, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Open-label study using ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy in patients with recurrent or metastatic head and neck and squamous cell cancer or advanced or metastatic cutaneous squamous cell carcinoma.

Timeline

Start: 2020-12-21
Primary completion: 2026-06
Completion: 2027-06

Publications

Cognetti DM, Curry JM, Johnson J, Kwon M, Su SY, Civantos F, Olazagasti C, Valentino J, Arnold SM, Bell RB, Gibson MK, Mannion K, Van Abel KM, Price KA, Dong H, Thorne AH, Suzuki T, Gillenwater AM. Safety and Efficacy Findings From a Phase Ib/II Study of ASP-1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Head Neck. 2026 Jan;48(1):160-174. doi: 10.1002/hed.70014. Epub 2025 Aug 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CETUXIMAB SAROTALOCAN	Other / unclassified	—	Intravenous
Subject	Cemiplimab	Monoclonal antibody	350 mg	—
Subject	Pembrolizumab	Monoclonal antibody	200 mg	—

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications